Transdermal Drug Delivery Systems Market Share 2021: Global Trends, Key Players, Industry Analysis Report to 2027

The transdermal drug delivery systems market was valued at $6,063.85 million in 2019 and is expected to reach $8,415.04 million by 2027. It is expected to grow at a CAGR of 4% from 2021 to 2027. The prevalence of chronic diseases where existing drug delivery systems, such as oral medications, have low efficacy due to primary metabolism of the liver, is leading the market.

A full report of Transdermal Drug Delivery Systems Market available at https://www.orionmarketreports.com/transdermal-drug-delivery-systems-market/53494/

Key Market Players

The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).

Transdermal Drug Delivery Systems Market Segmentations

By Type of Delivery System

Passive

• Matrix System
• Reservoir System

Active

• Structure Based
• Electrical Based
• Others

By Application

• Analgesics
• Hormone Replacement Therapy
• Cardiovascular Disorders
• Motion Sickness
• Smoking Cessation
• Others

(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)